Skip to main content
Glama

Regulatory Catalysts

by io.github.pipeworx-io

Resolve Entity

resolve_entity
Read-onlyIdempotent

"What's the ticker for…" / "find the CIK for…" / "what's the LEI for…" / "what's the RxCUI for…" / "look up the ID for…" / "what is X's official identifier" / "who owns X" / "is X a subsidiary of Y" — resolve a user-spoken NAME to the canonical/official identifiers other tools require as input. Use FIRST whenever you have a name but need an ID. SUPPORTED TYPES: "company" (cross-source identity spine: 10-digit CIK + ticker + company_name from SEC EDGAR, legal-entity LEI from GLEIF with parent/ultimate-parent/children ownership when the LEI resolves, and security FIGI from OpenFIGI — by exact ticker map when a ticker is implied, and otherwise by name search, so NON-EQUITY instruments that never have a ticker (municipal and corporate bonds, notes, authority debt) DO resolve here; when a name matches more than one instrument it asserts nothing and returns figi_candidates to pick from, which is the correct answer to an issuer name that does not identify a single bond; every identifier is labelled with the source that established it, and an identifier that could NOT be resolved is stated explicitly under unresolved rather than omitted — accepts ticker, CIK, ISIN, or company name as input; an ISIN like "CH0038863350" resolves to the LEGAL ENTITY that issued the security via the GLEIF ISIN-to-LEI mapping, covering non-US issuers EDGAR cannot reach), "drug" (returns RxCUI + ingredient + brand from RxNorm + pipeworx://rxnorm/concept/{rxcui} citation; accepts brand or generic name). LEI/FIGI enrichment degrades gracefully — if GLEIF or OpenFIGI is unavailable, the EDGAR identifiers still return. Each call cascades through several lookup endpoints internally — using resolve_entity replaces 2-3 manual lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valueYesFor company: ticker (AAPL), CIK (0000320193), or name. For drug: brand or generic name (e.g., "ozempic", "metformin"). Pass the ENTITY NAME ONLY — for a bond that is the ISSUER exactly as printed ("NEW YORK ST DORM AUTH"), never the question's full noun phrase ("NEW YORK ST DORM AUTH revenue bonds"): the FIGI lookup matches instrument names, so trailing security-class words match nothing.

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark the tool as read-only, idempotent, and non-destructive, and the description adds substantial behavioral context: internal cascading through multiple lookup endpoints, graceful degradation when GLEIF/OpenFIGI is unavailable, handling of non-equity instruments, and ISIN-to-LEI resolution for non-US issuers. There is no contradiction with annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is dense and appropriately front-loaded with purpose and usage, but the many parenthetical examples make it longer than strictly necessary. Each detail is relevant to correct invocation, so it earns most of its length.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness5/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

With no output schema, the description carries the burden of explaining return behavior, and it delivers: it enumerates returned identifiers for each type, cites the RxNorm source URL pattern, and clarifies fallback behavior when an enrichment source is unavailable. Nothing essential to calling the tool correctly is missing.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters5/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Though the schema already documents both parameters, the description significantly expands value: it gives accepted input formats (AAPL, 0000320193, CH0038863350, 'ozempic'), warns to pass the entity name only and not the full noun phrase, and explains how ISINs resolve to legal issuers. This is far beyond the schema's basic enum and string descriptions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with concrete user phrasings and states a clear verb-resource pair: resolve a user-spoken NAME to canonical/official identifiers other tools require as input. It lists supported entity types (company, drug) and the identifiers each returns, and positions itself as the first step for name→ID needs, distinguishing it from tools that consume those IDs.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines4/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

Explicitly says 'Use FIRST whenever you have a name but need an ID', which gives a clear trigger condition. It doesn't explicitly name when-not-to-use alternatives, but the sentence plus the supported-type scope gives adequate context.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

All Regulatory Catalysts toolsInspect
Try in Browser
RayrunBuild, deploy, and operate MCP servers without becoming an infrastructure team.ray.runAd

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.9/5.0
Disambiguation4/5

Most tools have distinct purposes, but the ask_pipeworx variants (ask_pipeworx, ask_pipeworx_beta, ask_pipeworx_grounded) and multiple Polymarket tools (bet_research, polymarket_edges, polymarket_arbitrage, etc.) could cause confusion for an agent selecting the appropriate tool.

Naming Consistency2/5

Tool names mix snake_case and camelCase inconsistently, with no strong verb_noun pattern. Examples include 'ask_pipeworx' vs 'discover_tools' vs 'validate_claim', indicating a lack of naming convention.

Tool Count2/5

33 tools is high for a single server, including many utility tools (memory, subscriptions) that seem peripheral to the core regulatory/data domain. This suggests scope creep and could overwhelm agents.

Completeness4/5

The tool set covers a wide range of regulatory and financial data needs, including company profiles, entity comparison, claim validation, FDA catalysts, and prediction market analysis. Minor gaps exist (e.g., no tool for editing data), but overall it is comprehensive for its stated purpose.

Resources